Sirolimus Eluting Coronary Stent System
- UID
- MFG/MD/2020/000236_dd9e936185c45bb38483da5470752fd4_8f64502f902f919eb16a8f63ff6480a0
- Device class
- Class D
- Brand name
- EnCruso RAL, EverMax RAL, Cruzon RAL, EverLite RAL
- License holder
- Nano Therapeutics Pvt. Ltd.
- Approving authority
- Central Drug Standards Control Organization, Ahmedabad
- Product information
- Sirolimus Eluting Coronary Stent System (EnCruso RAL, EverMax RAL, Cruzon RAL, EverLite RAL) is intended for use in the patient eligible for Percutaneous Transluminal Coronary Angioplasty (EnCruso RAL, EverMax RAL, Cruzon RAL, EverLite RAL). Sirolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions and in-stent restenotic lesion of length ˂52 mm in native coronary arteries with a reference vessel diameter of 2.00 to 4.50 mm
Sirolimus Eluting Coronary Stent System is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID MFG/MD/2020/000236_dd9e936185c45bb38483da5470752fd4_8f64502f902f919eb16a8f63ff6480a0. This device is marketed under the brand name EnCruso RAL, EverMax RAL, Cruzon RAL, EverLite RAL. The license holder is Nano Therapeutics Pvt. Ltd., and it is classified as Device Class Class D. The approving authority is Central Drug Standards Control Organization, Ahmedabad.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.